Immunic Inc (IMUX) Stock Price, Quote & News

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 255 9818

Website: imux.com

Address:

1200 Avenue of the Americas, Suite 200, New York, United States

FreeBeerTomorrow Apr. 25 at 10:37 AM

$IMUX Immunic, Inc. (IMUX) has a 1-for-10 reverse stock split scheduled to take effect this coming Monday, April 27, 2026. Total Outstanding Shares: Reduced from ~136.2 million to ~13.62 million. Based on current institutional and insider holdings (roughly 30-35% of total shares), the "free float" is estimated to be between 8.8 million and 9.5 million shares.

0 · Reply

TwongStocks Apr. 24 at 9:07 PM

Five NASDAQ reverse splits scheduled on Monday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Monday morning. $AIOS 1 for 20. Will reduce outstanding Class A shares from approx 64.99m to approx 3.25m. $CISS 1 for 7. Will reduce outstanding shares from approx 3.7m to approx 528k. $DRCT 1 for 4. Will reduce outstanding shares from approx 2.80m to approx 701k. $IMUX 1 for 10. Will reduce outstanding shares from approx 136m to approx 1.36m. $OCG 1 for 3. Will reduce outstanding shares from approx 5.81m to approx 1.94m.

0 · Reply

takingstock73 Apr. 24 at 7:47 PM

$IMUX .873 coincidence ? We may see a big move after split on Monday

1 · Reply

raticals Apr. 24 at 7:43 PM

$IMUX stock at .873. Warrant conversion price at .873 🧐🧐🧐🧐

1 · Reply

ONLYPHARMS Apr. 24 at 7:21 PM

$IMUX why did the split hasn’t even been under a dollar for a couple weeks

1 · Reply

Mattjen Apr. 24 at 5:21 PM

$IMUX this is nothing... I remember when we touched . 50. Thesis is still intact. We'll have a nice run pre-topline.... scale as we hit new ATHs and keep a nice % for BO/partnership/commercialization. I've been down almost 40k and up almost 100k, stay the course... longs are going to make serious $$$$$$

1 · Reply

Marcelkluetz Apr. 24 at 4:56 PM

$IMUX final day sub $1 folks :)

0 · Reply

Mdugs Apr. 24 at 5:00 AM

$IMUX watching to enter again.

0 · Reply

emin1903 Apr. 23 at 9:51 PM

$IMUX I will be making additional purchases next Monday in response to those who don't want imux to rise. There is currently no reason for imux to fall further... however, I think there are quite a significant number of short sellers... the possibility of short position squeezing will become clear tomorrow night.

1 · Reply

TwongStocks Apr. 23 at 7:40 PM

$IMUX Equity Corporate Actions Alert #2026 - 270 Information Regarding the Reverse Stock Split and CUSIP Number Change for Immunic, Inc. (IMUX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-270 Immunic, Inc. (IMUX) will effect a one-for-ten (1-10) reverse split of its Common Stock. The reverse stock split will become effective on Monday, April 27, 2026. In conjunction with the reverse split, the CUSIP number will change to 4525EP200.

0 · Reply

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Apr 17, 2026, 2:20 PM EDT - 8 days ago

Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says

Apr 9, 2026, 6:30 AM EDT - 16 days ago

Immunic to Participate in Scientific and Medical Conferences in April

Apr 1, 2026, 6:30 AM EDT - 24 days ago

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mar 31, 2026, 6:30 AM EDT - 25 days ago

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

Mar 18, 2026, 12:00 PM EDT - 5 weeks ago

Immunic Transcript: Stifel 2026 Virtual CNS Forum

Mar 11, 2026, 10:40 AM EDT - 6 weeks ago

Immunic Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 6:30 AM EDT - 6 weeks ago

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

Mar 3, 2026, 6:30 AM EST - 7 weeks ago

Immunic to Participate in Investor Conferences in March

Feb 26, 2026, 6:30 AM EST - 2 months ago

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Feb 17, 2026, 4:05 PM EST - 2 months ago

Immunic Announces Closing of Oversubscribed Private Placement Financing

Feb 13, 2026, 11:25 AM EST - 2 months ago

Immunic Stock Jumps After Pricing $400 Million Private Placement

Feb 13, 2026, 6:30 AM EST - 2 months ago

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Feb 4, 2026, 6:30 AM EST - 2 months ago

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Jan 7, 2026, 6:30 AM EST - 3 months ago

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

Dec 4, 2025, 9:35 AM EST - 5 months ago

Immunic Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 26, 2025, 6:30 AM EST - 5 months ago

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Nov 13, 2025, 6:30 AM EST - 5 months ago

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 6:30 AM EDT - 6 months ago

Immunic to Participate in Industry and Investor Conferences in November

Oct 1, 2025, 6:30 AM EDT - 7 months ago

Immunic to Participate in Scientific and Investor Conferences in October

Sep 25, 2025, 6:30 AM EDT - 7 months ago

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Sep 9, 2025, 6:30 AM EDT - 8 months ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Sep 8, 2025, 7:00 AM EDT - 8 months ago

Immunic Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 6:30 AM EDT - 8 months ago

Immunic to Participate in Investor and Scientific Conferences in September

Aug 7, 2025, 6:30 AM EDT - 9 months ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 24, 2025, 6:30 AM EDT - 10 months ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 5, 2025, 4:55 PM EDT - 11 months ago

Immunic Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 6:30 AM EDT - 11 months ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 3, 2025, 4:01 PM EDT - 11 months ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 2, 2025, 6:30 AM EDT - 11 months ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

May 29, 2025, 7:05 AM EDT - 11 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 28, 2025, 4:02 PM EDT - 11 months ago

Immunic, Inc. Announces Proposed Public Offering

May 2, 2025, 6:30 AM EDT - 1 year ago

Immunic to Participate in Scientific and Industry Conferences in May

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Immunic Transcript: Study Update

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 10, 2025, 1:00 PM EDT - 1 year ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 1 year ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 1, 2025, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Mar 12, 2025, 10:00 AM EDT - 1 year ago

Immunic Transcript: Leerink’s Global Healthcare Conference 2025

Mar 3, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Scientific and Investor Conferences in March

Feb 26, 2025, 6:30 AM EST - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 20, 2025, 7:30 AM EST - 1 year ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 12, 2025, 1:20 PM EST - 1 year ago

Immunic Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 4, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in February

Jan 7, 2025, 6:30 AM EST - 1 year ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Dec 5, 2024, 11:30 AM EST - 1 year ago

Immunic Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Participate in Investor Conference in December

Nov 13, 2024, 6:30 AM EST - 1 year ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunic Earnings Call Transcript: Q3 2024

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Sep 18, 2024, 3:05 PM EDT - 1 year ago

Immunic Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Immunic Earnings Call Transcript: Q2 2024

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 9, 2024, 6:30 AM EDT - 1 year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

May 8, 2024, 8:00 AM EDT - 2 years ago

Immunic Earnings Call Transcript: Q1 2024

Feb 22, 2024, 8:00 AM EST - 2 years ago

Immunic Earnings Call Transcript: Q4 2023

Nov 14, 2023, 8:00 AM EST - 2 years ago

Immunic Earnings Call Transcript: Q3 2023

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Immunic Earnings Call Transcript: Q2 2023

May 11, 2023, 8:00 AM EDT - 3 years ago

Immunic Earnings Call Transcript: Q1 2023

Feb 23, 2023, 8:00 AM EST - 3 years ago

Immunic Earnings Call Transcript: Q4 2022

Nov 3, 2022, 7:36 AM EDT - 3 years ago

Immunic Earnings Call Transcript: Q3 2022

FreeBeerTomorrow Apr. 25 at 10:37 AM

0 · Reply

TwongStocks Apr. 24 at 9:07 PM

0 · Reply

takingstock73 Apr. 24 at 7:47 PM

$IMUX .873 coincidence ? We may see a big move after split on Monday

1 · Reply

raticals Apr. 24 at 7:43 PM

$IMUX stock at .873. Warrant conversion price at .873 🧐🧐🧐🧐

1 · Reply

ONLYPHARMS Apr. 24 at 7:21 PM

$IMUX why did the split hasn’t even been under a dollar for a couple weeks

1 · Reply

Mattjen Apr. 24 at 5:21 PM

1 · Reply

Marcelkluetz Apr. 24 at 4:56 PM

$IMUX final day sub $1 folks :)

0 · Reply

Mdugs Apr. 24 at 5:00 AM

$IMUX watching to enter again.

0 · Reply

emin1903 Apr. 23 at 9:51 PM

1 · Reply

TwongStocks Apr. 23 at 7:40 PM

0 · Reply

emin1903 Apr. 23 at 7:23 PM

$IMUX Nine million shares were short-sold in March. The figures up to April 15 will be announced after tomorrow's market close. I believe at least 6-7 million more shares were short-sold in April. The company's split happening exactly on the 27th of the month cannot be a coincidence. The company chose this date. Let's not forget this: The majority of outstanding shares are not subject to trading. Approximately 50-60 million shares are actually in circulation. In this case, according to the actual circulating shares, 15/50=30% of the shares may have been short-sold. This, on the other hand, can seriously squeeze those who sell short on a good news that may come from the company. We can't know what the news will be, but in a positive scenario, we may see prices around 25-30 USD next week. The other possibility, in a worst-case scenario, is that we'll see prices drop to 5 USD.

1 · Reply

takingstock73 Apr. 23 at 5:34 PM

$IMUX PR drop of split , band aide officially off

1 · Reply